Wakamoto Pharmaceutical Co (TSE:4512) Ending Cash Position: 円0 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:4512 Wakamoto Pharmaceutical Co Ltd TSE:4512
63 GF Score
Price 円312.00
GF Value 円309.85
Valuation Fairly Valued
! 3 Warning Signs
View Full Analysis

What is Wakamoto Pharmaceutical Co Ending Cash Position?

Wakamoto Pharmaceutical Co TSE:4512 +1.30% 63 Ending Cash Position is 円0 Mil as of Mar. 2026. GuruFocus rates TSE:4512 with a GF Score™ of 63/100 and a GF Value™ of 円309.85 (Fairly Valued). The stock has 3 warning signs investors should review.

Wakamoto Pharmaceutical Co's Ending Cash Position for the quarter that ended in Mar. 2026 was 円0 Mil.

Wakamoto Pharmaceutical Co's annual Ending Cash Position declined from Mar. 2024 (円3,665 Mil) to Mar. 2025 (円2,955 Mil) and declined from Mar. 2025 (円2,955 Mil) to Mar. 2026 (円2,006 Mil).

Wakamoto Pharmaceutical Co Ending Cash Position Related Terms

Wakamoto Pharmaceutical Co Ending Cash Position Historical Data

* Premium members only.

The historical data trend for Wakamoto Pharmaceutical Co's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Wakamoto Pharmaceutical Co Ending Cash Position Chart

Wakamoto Pharmaceutical Co Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Ending Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3,231.89 3,879.33 3,664.65 2,954.76 2,006.18

Wakamoto Pharmaceutical Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
TSE:4512
63GF Score
Wakamoto Pharmaceutical Co Ltd TSE:4512
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Wakamoto Pharmaceutical Co Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Wakamoto Pharmaceutical Co's Ending Cash Position for the fiscal year that ended in Mar. 2026 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=2954.758+-948.583
=2,006

Wakamoto Pharmaceutical Co's Ending Cash Position for the quarter that ended in Mar. 2026 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=0+0
=0

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of 円0 Mil mean?
Wakamoto Pharmaceutical Co (TSE:4512) has a Ending Cash Position of 円0 Mil as of Mar. 2026. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Wakamoto Pharmaceutical Co and its competitors.
Is Wakamoto Pharmaceutical Co's Ending Cash Position too high?
Wakamoto Pharmaceutical Co's current Ending Cash Position is 円0 Mil. Overall, Wakamoto Pharmaceutical Co has a GF Score™ of 63/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Wakamoto Pharmaceutical Co's Ending Cash Position compare to ZTS?
Wakamoto Pharmaceutical Co's Ending Cash Position of 円0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Drug Manufacturers company?
A good Ending Cash Position depends on the Drug Manufacturers industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Wakamoto Pharmaceutical Co and its competitors. Wakamoto Pharmaceutical Co's current Ending Cash Position is 円0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Wakamoto Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Wakamoto Pharmaceutical Co (TSE:4512) is currently considered Fairly Valued. The stock's GF Value™ is 円309.85, compared to a current price of 円312.00 — trading 0.7% above its estimated fair value. The current Ending Cash Position is 円0 Mil. Wakamoto Pharmaceutical Co's overall GF Score™ is 63/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Wakamoto Pharmaceutical Co (TSE:4512), the current Ending Cash Position is 円0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Wakamoto Pharmaceutical Co (TSE:4512) Overvalued in 2026?

Based on GuruFocus' analysis, Wakamoto Pharmaceutical Co stock appears to be overvalued. The current stock price of 円312.00 is trading 0.7% above its estimated GF Value™ of 円309.85. GuruFocus considers Wakamoto Pharmaceutical Co to be Fairly Valued.

Key valuation signals for TSE:4512:

  • Ending Cash Position: 円0 Mil
  • GF Value™: 円309.85 vs. price of 円312.00 (0.7% above fair value)
  • GF Score™: 63/100 with 3 warning signs

No single metric tells the full story. See the TSE:4512 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Wakamoto Pharmaceutical Co Business Description

Address 2-2-2, Nihonbashi Honcho, Chuo-ku, Tokyo, JPN, 103-8330
Wakamoto Pharmaceutical Co Ltd is the pharmaceutical company based in Japan. It is engaged in the research and development, production and sale of ethical drugs and non-prescription drugs. The company specializes in therapeutic and diagnostic agents for ophthalmic disorders. It offers Strong Wakamoto, a gastrointestinal drug for digestion, the intestinal function controlling, and nutritional supply.
63GF Score

Get the complete analysis for TSE:4512

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円312.00
Price
円309.85
GF Value